In the absence of doxorubicin, silencing or inhibiting c-Abl or Arg inhibited p65 nuclear localization, and decreased basal and TNF-α-induced NF-κB transcriptional activity (Figure S6A–C), indicating that c-Abl/Arg activate NF-κB signaling in cancer cells. The gene discussed is ABL1; the disease is cancer.